A comprehensive view of astrazeneca ab. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Patent Issued for Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (USPTO 11655221)

US Patent Issued to AstraZeneca, Mitsubishi Tanabe Pharma on June 6 for "Compounds and their use" (Swedish, Japanese Inventors)

US Patent Issued to AstraZeneca on June 6 for "Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors" (British, Swedish Inventors)

AstraZeneca Files United States Patent Application for Dapagliflozin and Ambrisentan for the Prevention and Treatment of COVID-19

AstraZeneca ends Andexxa phase 4 trial early after achieving efficacy goal in patients on oral FXa-inhibitor treatment, including apixaban and rivaroxaban experiencing an intracranial haemorrhage; drug has been granted accelerated approval in the US

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count